W. Wegener

发表

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

G. Burmester, D. Goldenberg, O. Pradier, 2006, Arthritis research & therapy.

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome

C. Gordon, X. Mariette, J. Gottenberg, 2018, Arthritis & rheumatology.

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma

R. Elstrom, K. Rai, D. Goldenberg, 2011, Haematologica.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

M. Shah, P. Maliakal, D. Goldenberg, 2015, Clinical Cancer Research.

Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs)

V. Strand, P. Tak, D. Wallace, 2008 .

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.

J. Leonard, S. Ely, A. Cesano, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 ( hA 20): Phase I/II Results.

J. Leonard, B. Coiffier, M. Dyer, 2006 .

University of Birmingham Efficacy of Epratuzumab, an AntiCD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome:

X. Mariette, J. Gottenberg, H. Bootsma, 2018 .

University of Groningen Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjogren's Syndrome Post Hoc Analyses From the EMBODY Trials

X. Mariette, J. Gottenberg, H. Bootsma, 2018 .

Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.

J. Berlin, A. Bardia, J. Lang, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.

A. Bardia, D. Juric, Q. Hong, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

J. Leonard, B. Coiffier, M. Dyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab

L. Stenberg, S. Strand, T. Ohlsson, 2005, Clinical Cancer Research.

BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle

P. Chevallier, C. Bodet-Milin, F. Kraeber-Bodéré, 2013, European journal of haematology.

Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan

C. Bodet-Milin, F. Kraeber-Bodéré, J. Chatal, 2012 .

Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

D. Goldenberg, F. Morschhauser, W. Wegener, 2010, Leukemia & lymphoma.

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.

D. Huglo, M. Pfreundschuh, L. Trümper, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.

B. Ghadimi, C. Langer, D. Goldenberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

P. Chevallier, M. Béné, X. Thomas, 2015, The Lancet. Haematology.

Infectious imaging with indium-111-labeled nonspecific polyclonal human immunoglobulin.

A. Alavi, W. Wegener, M. Velchik, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab.

D. Isenberg, W. Wegener, H. Tahir, 2005, Rheumatology.

Magnetic resonance and fluorine-18 deoxyglucose imaging in the investigation of a spinal cord tumor.

J. Alavi, W. Wegener, A. Alavi, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Rapid diagnostic imaging of acute, nonclassic appendicitis by leukoscintigraphy with sulesomab, a technetium 99m-labeled antigranulocyte antibody Fab' fragment. LeukoScan Appendicitis Clinical Trial Group.

D. Goldenberg, W. Wegener, B. Barron, 1999, Surgery.

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Jeffrey A Jones, J. Byrd, R. Baiocchi, 2010 .

Phase I /II T rial o f E pratuzumab ( Humanized A nti-CD22 Antibody) i n I ndolent N on-Hodgkin's L ymphoma

J. Leonard, S. Ely, A. Cesano, 2003 .

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

M. Borowitz, P. Adamson, J. Reid, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

Xiaomin Lu, S. Hunger, M. Borowitz, 2011 .

Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabeled antigranulocyte antibody imaging agent.

D. Goldenberg, W. Wegener, A. Passalaqua, 2004, Journal of pediatric surgery.

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*

K. Rai, M. Kalaycio, D. Goldenberg, 2016, Leukemia & lymphoma.

Diagnostic imaging of musculoskeletal infection. Roentgenography; gallium, indium-labeled white blood cell, gammaglobulin, bone scintigraphy; and MRI.

W. Wegener, A. Alavi, 1991, The Orthopedic clinics of North America.

Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y

D. Huglo, F. Kraeber-Bodéré, J. Chatal, 2008 .

Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.

R. Elstrom, K. Rai, D. Goldenberg, 2009 .

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

H. Dombret, P. Chevallier, M. Béné, 2015, Haematologica.

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

C. Gordon, K. Kalunian, M. Petri, 2013, Rheumatology.

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.

C. Gordon, D. Isenberg, K. Kalunian, 2013, Rheumatology.

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

G. Burmester, T. Dörner, D. Goldenberg, 2006, Arthritis research & therapy.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

R. Korn, D. V. Von Hoff, M. Lowery, 2015, European journal of cancer.

Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma

J. Leonard, A. Cesano, D. Goldenberg, 2004, Clinical Cancer Research.

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

Jeffrey A Jones, J. Byrd, R. Baiocchi, 2015, British journal of haematology.

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.

J. Hajdenberg, E. Lam, M. Galsky, 2019, Journal of Clinical Oncology.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

R. Heist, D. Camidge, W. Messersmith, 2017, Clinical Cancer Research.

Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

A. Bardia, H. Rugo, J. Diamond, 2019, The New England journal of medicine.

Ventilation‐Perfusion Scintigraphy in an Adult with Congenital Unilateral Hyperlucent Lung

W. Wegener, M. Velchik, 1990, Clinical nuclear medicine.

Radioimmunotherapy of Pancreatic Adenocarcinoma

D. Goldenberg, R. Sharkey, D. Gold, 2013 .

Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer

T. Bekaii-Saab, D. Goldenberg, S. Goldsmith, 2012, Cancer.

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

A. Bardia, W. Messersmith, P. Maliakal, 2017, Cancer.

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

T. Witzig, D. Goldenberg, R. Sharkey, 2014, Haematologica.

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

A. Bardia, D. Juric, J. Diamond, 2018 .

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

J. Berlin, A. Bardia, R. Heist, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

J. Berlin, A. Bardia, T. Traina, 2016 .

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

D. Wallace, D. Goldenberg, W. Wegener, 2021, Annals of the Rheumatic Diseases.

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

J. Leonard, D. Goldenberg, A. Chadburn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meningioma extending through the skull. A palpable lesion with a scintigraphic doughnut sign.

W. Wegener, H. Williams, 1990, Clinical nuclear medicine.

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

R. Hauke, D. Goldenberg, R. Sharkey, 2011, Clinical Cancer Research.

IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

M. Shah, W. Messersmith, P. Maliakal, 2014 .

Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study.

T. Bekaii-Saab, D. Goldenberg, E. Mitchell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

I. Soubeyran, P. Moreau, R. Gressin, 2017, The Lancet. Haematology.

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

P. Moreau, R. Gressin, E. Deconinck, 2012 .

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

R. Elstrom, T. Witzig, D. Goldenberg, 2012 .

Durable complete responses from therapy with combined epratuzumab and rituximab

J. Leonard, D. Goldenberg, S. Schuster, 2008, Cancer.

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.

T. Lister, F. Morschhauser, P. Zinzani, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

J. Berlin, R. Goldberg, J. Marshall, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

J. Leonard, B. Coiffier, D. Goldenberg, 2005 .

Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results

A. Bardia, J. Diamond, J. O’Shaughnessy, 2018 .

Development of humanized antibodies as cancer therapeutics.

G. Griffiths, D. Goldenberg, H. Hansen, 2005, Methods.

Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma

D. Goldenberg, W. Wegener, H. Abdel-Nabi, 2000, Cancer.

Bronchobiliary fistula detected by cholescintigraphy.

W. Wegener, M. Velchik, G. M. Roth, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

A. Chanan-Khan, J. Kaufman, D. Goldenberg, 2013, British journal of haematology.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

H. Dombret, P. Chevallier, M. Béné, 2017, Haematologica.

858PSacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results

J. Hajdenberg, E. Lam, M. Galsky, 2017 .

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy

C. Bodet-Milin, F. Kraeber-Bodéré, D. Goldenberg, 2010, Cancer.

Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).

T. Bekaii-Saab, D. Goldenberg, S. Gulec, 2011, Journal of Clinical Oncology.

Positron emission tomography in the investigation of neuropsychiatrie disorders: Update and comparison with magnetic resonance imaging and computerized tomography

A. Alavi, W. Wegener, 1991 .

Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

Xiaomin Lu, S. Hunger, M. Borowitz, 2015, Pediatric blood & cancer.

Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.

D. Allman, D. Goldenberg, W. Wegener, 2014, JAMA dermatology.

Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL.

J. Leonard, B. Coiffier, D. Goldenberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

D. Siegel, A. Chanan-Khan, J. Kaufman, 2008 .

CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE)

D. Wallace, D. Goldenberg, W. Wegener, 2016, Lupus Science and Medicine.

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

J. Bussel, D. Goldenberg, W. Wegener, 2011 .

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography

D. Huglo, B. Dupas, C. Bodet-Milin, 2008, Haematologica.

Cancer Therapy : Clinical Treatment of Advanced Pancreatic Carcinoma with 90 Y-Clivatuzumab Tetraxetan : A Phase I Single-Dose Escalation Trial

R. Hauke, D. Goldenberg, R. Sharkey, 2011 .

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.

A. Bardia, M. Shah, W. Messersmith, 2015 .

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia

J. Bussel, D. Goldenberg, W. Wegener, 2016, Haematologica.

Low‐dose anti‐CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study

J. Bussel, D. Goldenberg, W. Wegener, 2013, British journal of haematology.

Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.

C. Kirsch, R. Naumann, J. Chatal, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

B. Coiffier, T. Lister, P. Zinzani, 2005 .

AB0633 Epratuzumab-treated SLE patients report improvements in health-related quality of life: Interim results from a us open-label extension study

V. Strand, K. Hobbs, W. Wegener, 2013 .

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

G. Burmester, T. Dörner, D. Goldenberg, 2008, Arthritis Research & Therapy.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

H. Dombret, P. Chevallier, M. Béné, 2015, Haematologica.

Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer

T. Bekaii-Saab, D. Goldenberg, S. Goldsmith, 2012, Cancer.

Durable complete responses from therapy with combined epratuzumab and rituximab

J. Leonard, D. Goldenberg, S. Schuster, 2008, Cancer.

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

J. Berlin, A. Bardia, J. Diamond, 2015 .

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

A. Bardia, R. Heist, W. Messersmith, 2015 .

Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.

J. Berlin, A. Bardia, M. Shah, 2015 .

A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study.

J. Berlin, J. Hecht, J. Marshall, 2015 .

First clinical experience with 90Y-radiolabeled humanized anti-MUC1 antibody (hPAM4) in patients with advanced pancreatic cancer: A phase I study

D. Goldenberg, L. Zuckier, S. Gulec, 2007 .

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

H. Dombret, P. Chevallier, M. Béné, 2016 .

Chemoimmunotherapy reinduction with epratuzumab in children with ALL with marrow relapse: A Children's Oncology Group (COG) pilot study (ADVL04P2)

M. Borowitz, P. Adamson, W. Carroll, 2007 .

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

R. Hauke, D. Goldenberg, R. Sharkey, 2011, Clinical Cancer Research.